Tirzepatide for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will assess whether a single subcutaneous dose of tirzepatide 7.5 mg , compared with saline placebo, increases total esophageal acid exposure time during a 96-hour wireless pH recording beginning about 48 hours after study medication.
Who Is on the Research Team?
Karthik Ravi, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for adults with obesity who may also have acid reflux (GERD). Participants should not have other major health issues that could interfere with the study or its results.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Tirzepatide
Trial Overview
The study compares a single injection of tirzepatide to a placebo (saltwater) to see if tirzepatide affects stomach and esophagus function, especially acid exposure, over several days.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
Tirzepatide 7.5 mg subcutaneous injection
Once subcutaneous injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.